window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-29484371-30');
Tuesday , August 4 2020
EMERGENCE MINDFUL 728.90
john overall 728×90
Mountains 728
ENTERPRISE 728
TRLA_728
Elizabeth 728
Spring Training 728
PBP_728
Emergence June 11 – Sep 11, 2020 728
Covid-19 Fund 728
Utep Football Generic 728
Home | News | Local News | $25k Grant Funds Promising Angiosarcoma Research

$25k Grant Funds Promising Angiosarcoma Research

Brad Bryan, Ph.D., an assistant professor at Texas Tech University Health Sciences Center El Paso (TTUHSC El Paso), has received a $25,000 grant from Angiosarcoma Awareness, Inc. to continue researching a new treatment for angiosarcoma, a cancer of the inner lining of blood vessels.

A recent study by Dr. Bryan’s lab demonstrated that the common heart drug propranolol is capable of halting the progression of highly lethal tumors called angiosarcomas. While the discovery was promising, “the mechanism by which this drug works is still unknown,” says

Brad Bryan, Ph.D., an assistant professor at Texas Tech University Health Sciences Center El Paso
Brad Bryan, Ph.D., an assistant professor at Texas Tech University Health Sciences Center El Paso

Bryan, researcher at TTUHSC El Paso’s Center of Emphasis in Cancer.

 

Funding from Angiosarcoma Awareness, Inc. will be used to further the knowledge of how propranolol works on the cancer.

“We are pleased to fund Dr. Brad Bryan with the Rebecca Robinson Angiosarcoma Awareness, Inc. grant to study propranolol in

angiosarcoma,” says Melissa González, president of Angiosarcoma Awareness.

“Angiosarcoma is a rare and aggressive disease with poor prognosis, and our organization strives to take steps towards funding important research to help understand what drives this malignancy, find new treatment strategies, and ultimately save the lives of patients battling this cancer.”

Dr. Bryan’s research lab will specifically study how propranolol affects angiosarcoma’s resistance to therapies, such as chemotherapy and radiation, which may be key to understanding how the drug stops the growth of the cancer.

About Staff Report

Staff Reports are just that, Staff Reporting the news. No skew, no opinion just the news. We pride ourselves on making sure that we bring you the news as soon as it is published, submitted or sent to us. No need to have a reporter rewrite or give their opinion. The facts or information, nothing more.

Check Also

Joyce Wilson elected Chair of Emergence Health Network Board of Trustees

Officials Emergence Health Network announced that Joyce Wilson will serve as chair for Emergence Health Network’s …

john overall 728×90
Get Shift Done 728
EMERGENCE MINDFUL 728.90
TRLA_728
Utep Football Generic 728
Emergence June 11 – Sep 11, 2020 728
Elizabeth 728
PBP_728
Covid-19 Fund 728
Mountains 728
Spring Training 728
ENTERPRISE 728